Loading stock data…
$17.57-1.53 (-8.01%)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
PROCEPT BioRobotics Corporation in the Healthcare sector is trading at $17.63 with a market capitalization of $1.1B. Wall Street consensus targets $22.33 (12 analysts), implying a +26.7% move over the next 12 months. The stock is currently near its 52-week low of $16.66, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $94.50M↑ | $83.13M↑ | $76.38M↓ | $83.33M↑ | $79.18M |
| Gross Profit | $62.38M↑ | $53.95M↑ | $46.31M↓ | $54.01M↑ | $51.75M |
| Operating Income | -$27.39M↑ | -$32.61M↓ | -$31.04M↓ | -$23.19M↓ | -$22.19M |
| Net Income | -$26.86M↑ | -$31.64M↓ | -$29.84M↓ | -$21.41M↓ | -$19.58M |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic syste...